Wenbo Sheng,
Haitao Jiang,
Hantao Yuan,
Sibo Li 
For correspondence:- Sibo Li Email: dr_lsb@163.com Tel:+8619921049422
Accepted: 5 February 2022 Published: 28 February 2022
Citation: Sheng W, Jiang H, Yuan H, Li S. Lugrandoside attenuates spinal cord injury by targeting peli1 and TLR4/NF-κB pathway to exert anti-inflammatory and anti-apoptotic effects. Trop J Pharm Res 2022; 21(2):245-251 doi: 10.4314/tjpr.v21i2.5
© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..
Purpose: To investigate the curative effect and mechanism of lugrandoside (LG) on spinal cord injury (SCI).
Methods: We probed the ex
Results: LG inhibited the activation and recruitment of glial cells by acting as a negative regulator of glial inflammation, and this reverse the targeting of peli1 and TLR4/NF-κB pathway. Furthermore, the in vivo data showed that LG exerted a neuroprotective effect, following SCI, via anti-inflammatory and anti-apoptotic effects. Furthermore, Peli1 and TLR4/NF-κB were suppressed by LG stimuli.
Conclusion: These results suggest that LG protects neural tissue against neuroinflammation and apoptosis by suppressing TLR4/NF-κB pathway and negatively targeting peli1. The findings may provide new insights into the treatment of spinal cord injury.
Fulltext in PDF